You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
A case of HER-2-positive recurrent breast cancer showing a clinically complete response to trastuzumab-containing chemotherapy after primary treatment of triple-negative breast cancer
|
|---|---|
| Published in |
World Journal of Surgical Oncology, November 2011
|
| DOI | 10.1186/1477-7819-9-146 |
| Pubmed ID | |
| Authors |
Hideo Shigematsu, Takayuki Kadoya, Yoshie Kobayashi, Keiko Kajitani, Tatsunari Sasada, Akiko Emi, Norio Masumoto, Rumi Haruta, Tsuyoshi Kataoka, Miyo Oda, Kouji Arihiro, Morihito Okada |
| Abstract |
We report a case of HER-2-positive recurrent breast cancer showing a clinically complete response to trastuzumab-containing chemotherapy 6 years after primary treatment of triple-negative breast cancer. The primary tumor was negative for HER-2 as determined by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) (1+, and ratio, 1.1), but examination of the recurrent lymph node metastasis showed positivity for HER-2 by FISH (ratio, 5.2). No lesions were detected in either her left breast or in other organs, and the patient was diagnosed as having HER-2-positive recurrent disease. Combination chemotherapy using weekly paclitaxel and trastuzumab was initiated, and a clinically complete response was achieved. This report suggests the benefit of routine evaluation of HER-2 status in recurrent breast cancer with the introduction of HER-2-targeting agents. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 20 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 20 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 4 | 20% |
| Student > Postgraduate | 3 | 15% |
| Other | 2 | 10% |
| Student > Master | 2 | 10% |
| Researcher | 2 | 10% |
| Other | 2 | 10% |
| Unknown | 5 | 25% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 7 | 35% |
| Biochemistry, Genetics and Molecular Biology | 1 | 5% |
| Nursing and Health Professions | 1 | 5% |
| Unspecified | 1 | 5% |
| Economics, Econometrics and Finance | 1 | 5% |
| Other | 3 | 15% |
| Unknown | 6 | 30% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 September 2016.
All research outputs
#6,376,108
of 22,656,971 outputs
Outputs from World Journal of Surgical Oncology
#178
of 2,038 outputs
Outputs of similar age
#39,397
of 142,328 outputs
Outputs of similar age from World Journal of Surgical Oncology
#1
of 46 outputs
Altmetric has tracked 22,656,971 research outputs across all sources so far. This one has received more attention than most of these and is in the 70th percentile.
So far Altmetric has tracked 2,038 research outputs from this source. They receive a mean Attention Score of 2.0. This one has done particularly well, scoring higher than 90% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 142,328 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 70% of its contemporaries.
We're also able to compare this research output to 46 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 97% of its contemporaries.